TCM
CLRB icon

Tang Capital Management’s Cellectar Biosciences CLRB Stock Holding History

Tang Capital Management’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-786
Closed -$471K – 18
2019
Q3 		$471K Sell
786
-1,481
-65% -$967K 0.08% 12
2019
Q2 		$1.48M Buy
+2,267
New +$1.55M 0.2% 9

Other funds holding CLRB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GPFA
Game Plan Financial Advisors Westlake, Ohio $222M AUM 22.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Tang Capital Management's CLRB Position: Q4 2019 in Review

Tang Capital Management sold out of Cellectar Biosciences (CLRB) in Q4 2019, closing a stake of 786 shares — an estimated $471K sold.

Tang Capital Management first reported a position in CLRB in Q2 2019 and held it in 2 quarters. The position peaked at $1.48M in Q2 2019. 10 funds tracked by Wall St. Rank hold CLRB as of Q4 2019.

  • Tang Capital Management reported no remaining Cellectar Biosciences position as of Q4 2019 after selling out during the quarter.
  • Tang Capital Management sold 786 Cellectar Biosciences shares in Q4 2019, an estimated $471K.
  • Tang Capital Management first reported a position in Cellectar Biosciences in Q2 2019 and held it in 2 quarters.
  • Tang Capital Management's Cellectar Biosciences position peaked at $1.48M in Q2 2019.
  • 10 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q4 2019.

Based on Tang Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.